Stock Trading

SHENZHEN, China, Sept. 14 /PRNewswire-FirstCall/ - HTDS www.htdsmedical.com The Company is pleased to provide the following update to its shareholders and followers on the (H1N1) Vaccine for Mellow Hope Inc, its China based subsidiary and other general business matters.

At the beginning of September, Mellow Hope completed the clinical trial of Influenza A (H1N1) Vaccine (Split Virion). The company received the clinical approval from the State Food and Drug Administration (SFDA) http://eng.sfda.gov.cn/eng. Production will be started shortly.

Mr. Terry Yuan CEO of HTDS said (sic) "Mellow Hope has received many inquiries from different countries, asking about the supply of this vaccine. The company is currently in overdrive preparing all the relevant documents to obtain the approval in all of these regions, from various jurisdictional authorities. We are very confident and expect that several significant deals will be finalized by the middle of October, or early November. We remind our shareholders that we beat out a lot of our competitors with our tenders, and we note that some are out in full force planting doubt about our business activities to our novice and unsuspecting shareholders."

Mr. Yuan exclaimed "Our business is doing fantastic! I can't say that any clearer or louder. Our revenues will spike in this 3rd or 4th quarter and once the numbers are released our shareholders will have plenty to smile about. Our audit has commenced, with our aspirations to become an OTCBB Company. I know that our North American office and our representatives there are busy providing the auditors data they require. Few weeks ago when we set the target of our share price of 3 cents per share we did so confidently. Now, with our H1N1 done and completed, HTDS en route to getting its audits completed, OTCBB listed, the cancer and anti aging project's of Slavica Bio Chem, actions we are taking against the naked shorting that has affected our stock, plus the sizable outstanding share reduction; in all fairness a 5 cent target is not an unreasonable or unrealistic target for HTDS."

On that note, Slavica Bio Chem is pleased to provide a video stream of its work. The web stream and English translations are available on www.htdsmedical.com under the section "Company News" The video is split in 3 segments. Permission was obtained from RTS TV for non commercial and informative use and to be placed on HTDS website.

Dr. Sanja Pekovic, Chief Project Scientist and Chief Strategy Officer summarized as following: "A few years ago Serbian government TV did a feature about our work, and it took a great public attention. It was about Multiple sclerosis, current therapies, there were also some patients, and our whole team. In the video Dr. Sanja Pekovic, Chief Project Scientist and Chief Strategy Officer and Prof Dr. Mirjana Stojiljkovic, Slavica Bio Chme's Medical Advisor can be seen and viewed in the TV documentary. Special thanks go out to Professor Rakic (See Biography Link) (http://www.sanu.ac.rs/English/Clanst...bisavRakic.pdf ). Professor Rakic was pivotal in making Slavica Bio Chem a reality a project that began in 2005 and has expanded to encompass cancer research and anti aging projects.

In other company news, the company through its IR Company retained a former economic crimes prosecutor to investigate trading of its security, and its belief that its security is subject to naked shorting. Mr. Essman is an International business attorney and former Assistant State Attorney of Hillsborough County (Tampa), Florida, where he served with the Special Prosecutions Unit for Economic and White Collar Crimes. His has offices in Tarpon Springs and St. Petersburg, Florida.

The issuer's shareholders and followers can expect updates on these matters shortly as the Company is adamant to get to the bottom of that topic and has instructed its barrister to vigorously pursue the matter.

Safe Harbor Statement

Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

A very nice play in the chat room today currently + 130% L2 shows the ask is getting a little thick here you may want to look at locking in profits imo. Congrats to all who is in.

Closed up 117% Congrats to all who got in very nice play. Keep this one on radar for a possible continuation.

HTDS cusip change to force short sellers to cover


HTDS and its advisors cannot and will not allow its security to be systematically erased off the books. Effective today Sept. 15, 2009 HTDS will request a new CUSIP number from its transfer agent. This "time out' which usually lasts 3-4 days to obtain the new CUSIP number will allow the company to prove to Pink Sheets that it had nothing to do with the improper "Promotion", and to complete the filings with Pink Sheets as per the Pink Sheets request see filing TAB or the direct link above.

More importantly, according to the rules, all broker dealers will have to reconcile their accounts and any short positions must be covered. This move by the HTDS management will also preserve the company equity and the last share price as recorded on close of September 14 2009.

During this 3-4 day "time out" the company will provide further updates and news so to assist shareholders with their positions and any short's not covered when the trading resumes. The issuer and its advisers feel that this is the most prudent and best course to take to protect its shareholders and its equity from the short seller's unscrupulous activities. The issuer apologizes for any inconvenience this has caused and assures its shareholders that the short term pain will be well worth the long term gain.


Safe Harbor Statement

Hard to Treat Diseases, Inc. (HTDS) Attorney Brad Essman Uncovers Reports of Retail Brokers Making False Statements
Press Release
Source: Hard to Treat Diseases
On Wednesday September 16, 2009, 11:36 am EDT
TORONTO, Sept. 16 /PRNewswire-FirstCall/ - Attorney Bradley Essman, acting on behalf of Hard to Treat Diseases, Inc. (HTDS) (Welcome to HTDS Medical) has uncovered irregularities in the actions of certain retail brokers who restricted trading in HTDS and LSDR stock.

The investigation of these matters is sponsored by Investor Relations firm Mina Mar Group, again acting aggressively protect its client companies. Mina Mar is currently suing a stock chat board and certain anonymous posters who make fraudulent "stock bashing" statements.

"We have received reports from our shareholders that certain retail brokers refused to accept buy orders in our securities and told our shareholders that the Depository Trust Clearing Corporation (DTC) mandated this action. However, DTC's legal chief told me personally that DTC is not authorized to take such action."

"This raises several burning questions: (1) what is the real reason such actions were taken, (2) how do these brokers have the authority to do this, (3) were these brokers acting in collusion, (4) who profited from this action, and (5) why are these brokers lying to their clients?"

"We plan on getting to the bottom of this situation in short order," said Mr. Essman.

Mr. Essman is an international business attorney and former Assistant State Attorney of Hillsborough County (Tampa), Florida, where he served with the Special Prosecutions Unit for Economic and White Collar Crimes. His has offices in Tarpon Springs and St. Petersburg, Florida.

Mr. Essman is investigating why certain retail brokers restricted trading in the securities of HTDS and LDSR.

Mina Mar President Miro Zecevic said, "Our clients are viable, revenue-producing companies with substantial assets. The more you look at them now, the more you can easily see that they have great potential for the future. We will never allow them to be desecrated by financial parasites, like naked short sellers, stock bashers and manipulators. We intend to investigate these matters thoroughly to see if there is any wrong doing. Our actions cause you to understand just how much we protect our clients."

HTDS and LDSR shareholders who have information concerning these issues or who wish to make reports on these matters are strongly urged to contact corporate@minamargroup.com We are especially interested in statements and written communications to our shareholders and other investors from retail brokers concerning trading restrictions and in collecting reports of investors being stopped from trading in our securities. We intend to investigate any and all allegations of manipulation and naked short selling.

In other company news, HTDS this morning filed its Adequate Disclosure documents to comply with Pink Sheets request to remove the "Skull and Bones" icon and ranking. The company will be posting the actual decision of Pink Sheets as a Filing on Pink Sheets for its shareholders and followers review. Pink Sheets is of the opinion that "a news release was put out by the company itself, talking about a "5 cent target" price for its stock by the CEO which was followed by an increase in trading volume" which justifies a down grade in ranking.

Pursuant to the issuer's news release of September 14, 2009, the issuer wishes to direct attention to the following link: Swine Flu Stocks

More updates to follow shortly.

Hard to Treat Diseases (HTDS) obtains H1N1 license with China SFDA
Press Release
Source: Hard to Treat Diseases
On Tuesday September 29, 2009, 2:02 pm EDT
SHENZHEN, China, Sept. 29 /PRNewswire-FirstCall/ - HTDS Welcome to HTDS Medical (HTDS) The issuer's China based operating subsidiary Mellow Hope through its exclusive business partner Zhejiang Tianyuan Bio-pharmaceutical Co., Ltd has been granted H1N1 license on September 24, 2009 by SFDA (China Authority) sfda. Mellow Hope is the exclusive agent of Zhejiang Tianyuan Bio-pharmaceutical Co., Ltd for International marketing and sales

Today, the issuer completed a set of filings in both Chinese and English translations on Pink Sheets Electronic OTC Markets - Quotation, Trading Systems, OTCQX, OTC Issuer Services see filing titled "Supplemental Information - H1N1 License and Supporting Documents" or this direct link Quotes, Company Info, Filings, News, Short Interest - Hard to Treat Diseases, Inc. - HTDS. Also, the company promised in two separate news releases of September 2009 that it will release the name of its exclusive partnership. The filings and supporting H1N1 documents on Pink Sheets are self explanatory.

The company believes that there is a naked short interest in the stock and the company has retained counsel to investigate this matter and possible market manipulation by short sellers. In this connection, the Company has received numerous allegations and complaints from shareholders. In addition, the company has been the victim of anonymous "stock bashing" and a campaign of negative publicity, a smear campaign. In fact, there is a lawsuit in progress on some of these issues.

"We believe that the full potential of our H1N1 vaccine business has yet to be realized in our stock price and this report outlines some of the issues involved," said HTDS CEO Terry Yuan. "Take a good look at all that is going on now for HTDS and you may be surprised to find that when you do so, you share our enthusiasm for HTDS. H1N1 is done and completed so we are eager to start to profit from this huge demand from customers who want to now buy HTDS products immediately. We are also moving with great energy to get our audits completed and get OTCBB listed. When you look at the potential cancer and anti-aging projects of Slavica Bio Chem it is easy to find yourself strongly visualizing their enormous potential. HTDS is also taking aggressive action against the suspected naked shorting that has apparently affected our stock so we can remove all possible barriers to appreciation and give our investors confidence in the future of their investment. Further, most people do not seem to realize we have recently made a sizable recent reduction in our stock outstanding and understand fully what that means. When you add all the excitement all this has created to our eagerness to move forward, it can cause you to start to see that we are on verge of a major expansion. We believe you have to find yourself putting HTDS in that spot in your mind where you would put a company that has virtually unlimited upside. We look forward to the future and we believe that a year from now we will find ourselves looking back on back on this time as one where we all participated in a major expansion."

Hard to Treat Diseases (HTDS) Management Discussion
Press Release
Source: Hard to Treat Diseases
On Thursday October 1, 2009, 1:40 pm EDT

Pink Sheets Filings Reply To Shareholders FAQ on Various Past News and
General Corporate Update

SHENZHEN, China, Oct. 1 /PRNewswire-FirstCall/ - HTDS Welcome to HTDS Medical (HTDS) The issuer's China based operating subsidiary Mellow Hope and Serbia operating Subsidiary Slavica Bio Chem are providing news release to bring attention to today's Pink Sheets filing. The filing found on Pink Sheets HTDS listing or this link Quotes, Company Info, Filings, News, Short Interest - Hard to Treat Diseases, Inc. - HTDS

The company hopes that this filing bring its followers and shareholders up to date with various events and pending transactions, and to provide an update on past news releases. The filing is intensive 4 pages covering short sellers, naked short positions. The superficial "skull and bones" icon effecting HTDS, IP rights, cancer project and unsolicited buyer, H1N1 business and pending foreign defamation judgment and other FAQ topics of HTDS followers and shareholders.

The filing on Pink Sheets is timed to coincide and release at the same time as this news release shortly after 1:30pm EST.

To receive regular updates on HTDS please sign up or opt in with your email address at this link Update

Hard to Treat Diseases (HTDS) Receives Equity Capital Follow Up Report
Press Release
Source: Hard to Treat Diseases
On Monday October 5, 2009, 2:45 pm EDT
Company receives follow up report and files with Pink Sheets

LONDON, Oct. 5 /PRNewswire-FirstCall/ - HTDS Welcome to HTDS Medical (HTDS) - The issuer's China based operating subsidiary Mellow Hope and Serbia operating subsidiary Slavica Bio Chem are providing this news release to bring attention to today's Pink Sheets filing. The filing called "Equity Capital Management Update On HTDS Report" can be found on Pink Sheets HTDS listing under the tab "Filings" or this direct link: Quotes, Company Info, Filings, News, Short Interest - Hard to Treat Diseases, Inc. - HTDS

The report, amongst other things addresses the following topics: Background of the company, Swine Flu (H1N1), Pink Sheets "Skull and Bones" to name a few.

The filing on Pink Sheets is timed to coincide and release at the same time as this news release shortly after 2:25 pm EST.

In other company news, as previously announced with the Canadian Pharmaceutical company continued interest and aspirations towards the cancer research and those IP rights of HTDS Slavica Bio Chem subsidiary will shortly be launching the cancer project and the cancer project web site Welcome to HTDS Medical. This, together with medical posters and other relevant information relating to the project will also be posted as a filing on Pink Sheets and on the company corporate web site Welcome to HTDS Medical shortly.

To receive regular updates on HTDS please sign up or opt in with your email address at this link: Update.

Hard to Treat Diseases (HTDS) Obtains GMP Certificate from Russian FDA
Press Release
Source: Hard to Treat Diseases
On 2:30 pm EDT, Wednesday October 7, 2009
Hepatitis A Live Attenuated Vaccine and Planned Forward Stock Split 2-1

SHENZHEN, China, Oct. 7 /PRNewswire-FirstCall/ - HTDS Welcome to HTDS Medical (HTDS) - The issuer's China based operating subsidiary Mellow Hope www.mellowhope.com is pleased to announce that its Hepatitis A Live Attenuated Vaccine (Brand name: Mevac-A) associate operation plant has obtained the GMP Certificate (Good Manufacturing Practice See Description Good manufacturing practice - Wikipedia, the free encyclopedia) from the Russian FDA. http://www.who.int/hiv/HIVCP_RUS.pdf

Since on or about September 24, 2009 when Mellow Hope announced through its exclusive business partner Zhejiang Tianyuan Bio-pharmaceutical Co., Ltd Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd. that it has been granted H1N1 license by SFDA (China Authority) sfda interests in H1N1 began to grow Internationally with the company. Mellow Hope is the exclusive agent of Zhejiang Tianyuan Bio-pharmaceutical Co., Ltd for International marketing and sales.

New contracts and sales progress on H1N1 will be disclosed as they occur in subsequent HTDS press releases.

In other company news and events the company with this release brings attention to its Pink Sheets filing dated October 6, 2009 Supplemental Information- Forward Stock Split 2-1 HTDS Naked Short Positions and Remedies.

In summary, HTDS is considering having its shareholders approve a resolution on to make a two for one stock forward split. After due consideration, HTDS directors are recommending that the shareholders approve amending and restating our Articles of Incorporation in order to consolidate numerous amendments in the Articles that have occurred over the years, to create a two-for-one forward split, to prepare the Company to move up to the OTC Bulletin Board, and to add certain anti-takeover and other provisions. HTDS sees this forward split as one way to force short sellers to cover their current positions. Other remedies are also under consideration to thwart the short sellers or "oversold" positions of HTDS.

To receive regular updates on HTDS please sign up or opt in with your email address at this link Mina Mar Group

Slavica Bio Chem (HTDS) Subsidiary Medical Team Message
Press Release
Source: Hard to Treat Diseases
On 1:00 pm EDT, Monday October 12, 2009
BEOGRAD, Serbia, Oct. 12 /PRNewswire-FirstCall/ - HTDS Welcome to HTDS Medical (HTDS) - The issuer's Serbia based operating subsidiary Slavica Bio Chem Homepage | Slavica Biochem is providing an audio recording and a transcript of its message via Pink Sheets Filing service. The audio recording a wav file can be played by visiting Mina Mar Group - HTDS audio files.

The transcript and the audio recording covers scientific topics and work being done by the issuer's Serbian Slavica Bio Chem operating subsidiary. Other topics touched or addressed are Multiple Sclerosis and Traumatic Brain Injury, The newly founded MindUp project is dealing with cancer treatment. Team leader from Slavica Biochem is Dr Mirjana Stojiljkovic of the Institute of Biological Research "Sinisa Stankovic," Belgrade, Serbia. The MindUp cancer project is to be affiliated and or sold or assigned (transaction not yet ratified) to a Canadian Pharmaceutical company. This is the introduction of Dr. Sabera Ruzdijic as chief scientist of MindUp the cancer project.

Substances used include existing in-use drugs, such as RIBAVIRIN and TIAZOFURIN. RIBAVIRIN an already FDA approved drug and used in human clinical practice as antiviral drug, by the trade name: VIRAZOLE® There has been very successful treatment of Respiratory Syncytial Virus in children, hepatitis C, SARS and HIV. TIAZOFURIN. It has been granted orphan-drug status by FDA for the Treatment of Chronic Myelogenous Leukemia (CML). There are Phase II clinical trials of anticancer drugs.

This is experimental data that Slavica Biochem group obtained on laboratory animals. Preliminary experiments will begin within a project aimed at promoting stem cell graft survival in the model of traumatic brain injury in rats.

The company invites its followers to review all the Pink Sheets filings and the full transcript and to listen to the audio recording of the scientists in Belgrade.

In other company news, HTDS management has been informed that there is an independent petition brought by a number of shareholders in support of HTDS at HTDS Removal of Caveat Emptor Petition. This is a petition to the Pink Sheets to remove the Caveat Emptor status from HTDS stock listing. To date, over 600 concerned shareholders have clicked on that link and signed the petition!

To our shareholders: We share your concern that the action of the Pink Sheets in giving us the skull and crossbones and failing to remove for so long is hurting our stock price and causing people not to buy our stock. We agree that the reason given for continuing this improper action -- that there may be other people making naked short sales in the stock -- is not a good reason to negatively label our company. We know of no other instance where this has happened to another company in the Pink Sheets whose stock has short sellers. We are making every effort to remedy this situation.

On behalf of HTDS management, employees and the patients that we help with our treatments, we thank our shareholders for their strong support. We are all grateful for such loyal shareholders and their spontaneous demonstration of confidence in the future of our company. We pledge to re-double our efforts to create value for you no matter what opposition we face.

To receive regular updates on HTDS please sign up or opt in with your email address at this link Mina Mar Group